Swine Flu Declared a Pandemic by World Health Organization: Distributors of PURE Bioscience’s SDC-Based Disinfectants are Well-Positioned to Respond Immediately

PURE Bioscience (NASDAQ: PURE), creators of the patented silver dihydrogen citrate (SDC) antimicrobial, responded to the declaration by the World Health Organization that the Swine Flu outbreak has become a pandemic by announcing that its distributors of the silver dihydrogen citrate-based disinfectant are well-positioned to respond immediately to this growing health crisis.

In May, the U.S. Environmental Protection Agency (EPA) published a list of antimicrobial products, including SDC-based disinfectants, effective against the 2009 H1N1 flu strain based on their effectiveness against other influenza A virus strains. EPA believes, based on available scientific information, that the currently registered influenza A virus products will be effective against the 2009-H1N1 flu strain and other influenza A virus strains on hard, non-porous surfaces. The EPA notice also reminds end users to always follow label instructions, paying special attention to the product’s dilution rate (if applicable) and contact time to ensure safe and effective use of these products, and to confirm that the product is labeled specifically for the site on which it will be used such as: hospitals, healthcare facilities, schools, offices or homes.

Disinfectants containing PURE’s SDC antimicrobial also meet the recommendation by the CDC for infection control of H1N1 in both home and healthcare settings. Guidance published by the CDC on April 24, 2009 for infection control in healthcare settings advises that “disinfection strategies used during influenza seasons can be applied to the environmental management of swine influenza.” Additional guidance published on April 25, 2009 for infection control in the home recommends keeping “surfaces (especially bedside tables, surfaces in the bathroom, and toys for children) clean by wiping them down with a household disinfectant according to directions on the product label.”

Disinfectants using PURE’s SDC-based antimicrobial have been registered by the EPA specifically for use on children’s toys, cribs, high chairs and other sensitive areas of the home as well as for use on hard surfaces in multitudes of environments, including hospitals, schools and offices.

Michael L. Krall, President and CEO of PURE Bioscience, stated, “The benefits of using SDC-based disinfectants, available under many private brands, make it an ideal and powerful choice as individuals, institutions, businesses and governments seek to stem the spread of H1N1. Our distributors are well-positioned to respond regionally, nationally and internationally to deliver product immediately, and PURE has the manufacturing capability to supply the distribution pipeline.”

PURE Bioscience’s broad spectrum SDC-based disinfectant completely eliminates bacteria, viruses and fungi and is registered with the EPA under the trade name Axen30. It is sold through a variety of distributors under more than a dozen private label brands. Independent lab studies and resulting EPA-registered claims document that PURE’s disinfectant kills resistant strains of bacteria, including MRSA (Methicillin-resistant Staphylococcus aureus), CA-MRSA, PVL-MRSA and VRE (Vancomycin resistant Enterococcus faecium) in just 2 minutes. In addition, SDC-based disinfectants provide a 30-second kill and 24-hour residual protection against Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella choleraesuis. Notable viral efficacy claims for PURE’s disinfectant include a 3-minute kill against Human Corona virus (SARS surrogate) and Rotavirus and a 10-minute kill against Norovirus, Human Influenza A and Avian Influenza A (Bird Flu). Moreover, SDC-based disinfectants are odorless, colorless, non-corrosive, non-flammable and are compatible with other disinfecting and cleaning chemicals.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company’s current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contacts

PURE Investor Contact:
Bibicoff + MacInnis, Inc.
Terri MacInnis, Dir. of Investor Relations
818-379-8500
terri {at} bibimac(.)com
or
PURE Media Contact:
Gutenberg Communications
Michael Gallo
212-239-8594
mgallo {at} gutenbergpr(.)com